Dr Reddys Laboratories
BSE: 500124 | NSE: DRREDDY | ISIN: INE089A01023 | SECTOR: Biotechnology & DrugsOpen
4,570.05High
4,639.00Low
4,570.05Prev Close
4,602.45P/E
-Median P/E
-P/B
-Median P/B
-Market Cap
770.55BVolume
3.44KVol. (20 day Avg.)
0PEG
-Div.Yield
-Bid
-Ask
4,635.15
Company Description
- Biotechnology & Drugs
BSE
500124NSE
DRREDDYISIN
INE089A01023
Dr. Reddy's Laboratories Limited is an India-based pharmaceutical company. The Company’s segments include Global Generics, which is engaged in manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics); Pharmaceutical Services and Active Ingredients (PSAI), which is engaged in manufacturing and marketing active pharmaceutical ingredients and intermediates for finished pharmaceutical products; Proprietary Products, which focuses on research and development of differentiated formulations and Others, which consists of the Company’s wholly-owned subsidiary, Aurigene Discovery Technologies Limited, which is a discovery stage biotechnology company developing novel and therapies in the fields of oncology and inflammation.
Company Officers
K. Satish Reddy
Chairman of the BoardG. V. Prasad
Co-Chairman of the Board, Managing DirectorErez Israeli
Chief Executive OfficerParag Agarwal
Chief Financial OfficerPatrick Aghanian
Chief Executive Officer, European GenericsMarc Kikuchi
Chief Executive Officer, North America GenericsM. Ramana
Chief Executive Officer, Branded Markets (India and Emerging Markets)Deepak Sapra
Chief Executive Officer, API and ServicesArchana Bhaskar
Chief Human Resource OfficerMukesh Rathi
Chief Digital and Information Officer